Doses of Moderna Covid-19 bivalent were administered BUD to total of 17 recipients; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses of Moderna Covid-19 bivalent were administered BUD to total of 17 recipients) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 215K22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses of Moderna Covid-19 bivalent were administered BUD to total of 17 recipients) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses of Moderna Covid-19 bivalent were administered BUD to total of 17 recipients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Doses of Moderna Covid-19 bivalent were administered BUD to total of 17 recipients).    Concomitant medication was not reported. Treatment medication was not reported.  This case contains information for the 1st of 17 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-713300, US-MODERNATX, INC.-MOD-2023-713273, US-MODERNATX, INC.-MOD-2023-713283, US-MODERNATX, INC.-MOD-2023-713284, US-MODERNATX, INC.-MOD-2023-713285, US-MODERNATX, INC.-MOD-2023-713286, US-MODERNATX, INC.-MOD-2023-713288, US-MODERNATX, INC.-MOD-2023-713289, US-MODERNATX, INC.-MOD-2023-713290, US-MODERNATX, INC.-MOD-2023-713292, US-MODERNATX, INC.-MOD-2023-713293, US-MODERNATX, INC.-MOD-2023-713294, US-MODERNATX, INC.-MOD-2023-713295, US-MODERNATX, INC.-MOD-2023-713296, US-MODERNATX, INC.-MOD-2023-713297, US-MODERNATX, INC.-MOD-2023-713298 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-713289:Patient 8 out 17 patients US-MODERNATX, INC.-MOD-2023-713288:Patient 7 out 17 patients US-MODERNATX, INC.-MOD-2023-713295:Patient 13 out 17 patients US-MODERNATX, INC.-MOD-2023-713297:Patient 15 out 17 patients US-MODERNATX, INC.-MOD-2023-713284:Patient 4 out 17 patients US-MODERNATX, INC.-MOD-2023-713286:Patient 6 out 17 patients US-MODERNATX, INC.-MOD-2023-713290:Patient 9 out 17 patients US-MODERNATX, INC.-MOD-2023-713293:Patient 11 out 17 patients US-MODERNATX, INC.-MOD-2023-713300:Patient 17 out 17 patients US-MODERNATX, INC.-MOD-2023-713292:Patient 10 out 17 patients US-MODERNATX, INC.-MOD-2023-713273:Patient 2 out 17 patients US-MODERNATX, INC.-MOD-2023-713296:Patient 14 out 17 patients US-MODERNATX, INC.-MOD-2023-713294:Patient 12 out 17 patients US-MODERNATX, INC.-MOD-2023-713285:Patient 5 out 17 patients US-MODERNATX, INC.-MOD-2023-713283:Patient 3 out 17 patients US-MODERNATX, INC.-MOD-2023-713298:Patient 16 out 17 patients